Table 3.
Examples of clinical trials using immunotherapy in glioblastoma.
| Trial | Molecular Target | Type of Therapy | Status |
|---|---|---|---|
| NCT03726515 | EGFRvIII | CAR T + Pembrolizumab | Completed (phase I) |
| NCT00895180 | PDGFR | Monoclonal antibody | Completed (phase II) |
| NCT01454596 | EGFRvIII | CAR T | Completed (phase I/II) |
| NCT00128635 | DNA–histone H1 complex | Monoclonal antibody | All completed (phase I and phase II the NCT00004017) |
| NCT00004017 | |||
| NCT00509301 | |||
| NCT01498328 | EGFRvIII | Vaccine | Completed (phase II) |
| NCT01109095 | HER2 | CAR T | Completed (phase I) |
| NCT04214392 | CLTX | CAR T | Recruiting (phase I) |
| NCT03174197 | PD-1/PD-L1 | Monoclonal antibody with a checkpoint inhibitor function + RT + TMZ | Active, not recruiting (phase I/II) |
| NCT04443010 | EDB-FN | Cytokines + TMZ | Recruiting (phase I/II) |
| NCT03047473 | PD-1/PD-L1 | Monoclonal antibody with a checkpoint inhibitor function | Completed (phase II) |
| NCT02049489 | CD133 | Vaccine | Completed (phase I) |
| NCT05024175 | EGFRvIII | CAR-T | Not yet recruiting (phase I) |
| NCT04047706 | PD-1/PD-L1 | Monoclonal antibody with a checkpoint inhibitor function | Active, not recruiting (phase I) |
| NCT02017717 | PD-1/PD-L1 | Monoclonal antibody with a checkpoint inhibitor function | Active, not recruiting (phase III) |
| NCT04661384 | IL13Rα2 | CAR T | Recruiting (phase I) |
| NCT01480479 | EGFRvIII | Vaccine + TMZ | Completed (phase III) |
| NCT04003649 | IL13Rα2 | CAR T with checkpoint inhibition | Recruiting (phase I) |
TMZ—Temozolomide; CAR T—Chimeric antigen receptor T-cell.